Key result
MitraClip XTR successfully reduces severe TR and prevents HF hospitalizations for over 6 months.
Why the study?
Severe tricuspid valve regurgitation is associated with high cardiovascular mortality and safe, feasible interventional treatments are clinically relevant.
Case Report (n=1)
The new MitraClip XTR System with wider clip arms is feasible and effective for percutaneous edge-to-edge repair of complex tricuspid regurgitation with a large coaptation gap.
No takes yet. Share an insight, caveat, or question.
Supports feasibility of MitraClip XTR in complex TR; hypothesis-generating and requires prospective validation before practice change.
Mueller et al. (2020) conducted a case report in Severe tricuspid valve regurgitation (n=1). MitraClip XTR System was evaluated on Reduction of TR and heart failure symptoms. Percutaneous edge-to-edge tricuspid valve repair using the MitraClip XTR System successfully reduced severe tricuspid regurgitation and prevented heart failure hospitalizations for over 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: